|
|
Suppliers for
Vorapaxar
|
Properties | CAS |
618385-01-6 | Formula |
C29H33FN2O4 |
|
12 Registered suppliers
More details are to be found here
More details are to be found here
Molecular Formula: C29H33FN2O4 Molecular Weight: 492.5817232
Molecular Formula: C29H33FN2O4 Molecular Weight: 492.5817232
Molecular Formula: C29H33FN2O4 Molecular Weight: 492.5817232
Molecular Formula: C29H33FN2O4 Molecular Weight: 492.5817232
Molecular Formula: C29H33FN2O4 Molecular Weight: 492.5817232
Description : SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients. - Molecular Weight :492.58
- Purity :0.98
Molecular Formula : C29H33FN2O4 Canonical SMILES : CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C InChI : InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1 InChIKey : ZBGXUVOIWDMMJE-QHNZEKIYSA-N Application : Platelet Aggregation Inhibitors Synonyms : N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate; Sch 530348;
More details are to be found here
Description : SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients. - Molecular Weight :492.58
- Purity :0.98
Molecular Formula : C29H33FN2O4 Canonical SMILES : CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C InChI : InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1 InChIKey : ZBGXUVOIWDMMJE-QHNZEKIYSA-N Application : Platelet Aggregation Inhibitors Synonyms : N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate; Sch 530348;
More details are to be found here
Description : SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients. - Molecular Weight :492.58
- Purity :0.98
Molecular Formula : C29H33FN2O4 Canonical SMILES : CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C InChI : InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1 InChIKey : ZBGXUVOIWDMMJE-QHNZEKIYSA-N Application : Platelet Aggregation Inhibitors Synonyms : N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate; Sch 530348;
More details are to be found here
More details are to be found here
More details are to be found here
Detailed information on the suppliers of
Vorapaxar
|
Properties:
... more properties and specification on Vorapaxar
|
|
Privileged suppliers
Last update 2024-06-10
|